Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
or
Menu

Albireo Pharma Inc (ALBO)

[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 310,143
  • Shares Outstanding, K 11,970
  • Annual Sales, $ 1 K
  • Annual Income, $ -24,410 K
  • 36-Month Beta 1.74
  • Price/Sales 22.74
  • Price/Cash Flow N/A
  • Price/Book 2.28

Analyst Rating / Earnings Estimates

Current Rating
See More
Strong Buy
Based on 5 analysts offering recommendations.
Earnings Estimates - Current Qtr 12/31/18
See More
  • Average Estimate -1.12
  • Number of Estimates 5
  • High Estimate -0.80
  • Low Estimate -1.31
  • Prior Year -0.55
  • Growth Rate Est. (year over year) -103.64%

Price Performance

See More
Period Period Low Period High Performance
1-Month
21.80 +16.01%
on 01/28/19
26.74 -5.42%
on 02/05/19
+1.14 (+4.72%)
since 01/18/19
3-Month
19.10 +32.41%
on 12/21/18
26.98 -6.26%
on 12/03/18
+0.03 (+0.12%)
since 11/21/18
52-Week
19.10 +32.41%
on 12/21/18
39.35 -35.73%
on 03/16/18
-8.66 (-25.51%)
since 02/21/18

Most Recent Stories

More News
Albireo Granted Orphan Designation by European Commission For Lead Product Candidate A4250 for Treatment of Biliary Atresia

Expands lead product candidate's development potential in rare cholestatic liver diseases

ALBO : 25.29 (-2.39%)
Albireo Reports Third Quarter 2018 Financial Results

Odevixibat selected as International Nonproprietary Name (INN) for A4250

ALBO : 25.29 (-2.39%)
Albireo to Report Third Quarter 2018 Financial Results and Host Conference Call and Webcast on November 13, 2018

Albireo Pharma, Inc. (Nasdaq: ALBO), a clinical-stage orphan pediatric liver disease company developing novel bile acid modulators, today announced that its third quarter financial results will be reported...

ALBO : 25.29 (-2.39%)
Report: Exploring Fundamental Drivers Behind Manulife Financial, Baozun, AstraZeneca, Insight Enterprises, Albireo Pharma, and Mobile TeleSystems OJSC -- New Horizons, Emerging Trends, and Upcoming Developments

In new independent research reports released early this morning, Market Source Research released its latest key findings for all current investors, traders, and shareholders of Manulife Financial Corp...

NSIT : 57.04 (-0.97%)
AZN : 40.43 (-0.25%)
ALBO : 25.29 (-2.39%)
MFC : 16.80 (-0.47%)
BZUN : 34.58 (-2.97%)
MBT : 7.59 (-0.13%)
Albireo Granted Orphan Drug Designation For Lead Product Candidate A4250 for Treatment of Alagille Syndrome

Albireo Pharma, Inc. (Nasdaq: ALBO), a clinical-stage orphan pediatric liver disease company developing novel bile acid modulators, today announced the U.S. Food and Drug Administration (FDA) has granted...

ALBO : 25.29 (-2.39%)
Albireo Receives FDA Fast Track Designation for A4250

Albireo Pharma, Inc. (Nasdaq: ALBO), a clinical-stage orphan pediatric liver disease company developing novel bile acid modulators, today announced the U.S. Food and Drug Administration (FDA) has granted...

ALBO : 25.29 (-2.39%)
Albireo Announces Research on Cholestatic Liver Diseases to be Presented at Major North American Liver Meetings

Study results to be presented at NASPGHAN demonstrate reductions in bile acids and bilirubin are highly associated with decreased aggregate need for liver transplant in PFIC patients

ALBO : 25.29 (-2.39%)
Albireo Provides First Quarter 2018 Business Update

First patient enrolled in Phase 3 trial of IBAT inhibitor A4250 in PFIC

ALBO : 25.29 (-2.39%)
Albireo Pharma, Inc. to Host Earnings Call

NEW YORK, NY / ACCESSWIRE / May 17, 2018 / Albireo Pharma, Inc. (NASDAQ: ) will be discussing their earnings results in their Q1 Earnings Call to be held on May 17, 2018 at 8:30 AM Eastern Time.

ALBO : 25.29 (-2.39%)
Albireo Enrolls First Patient in Phase 3 PFIC Trial of A4250

-- Pivotal program in rare and life-threatening pediatric liver disorder underway --

ALBO : 25.29 (-2.39%)

Barchart Technical Opinion

The Barchart Opinion rating is a Hold. Short term, the outlook is Falling.

See More Share

Trade ALBO with:

Business Summary

Albireo Pharma, Inc. is a biopharmaceutical company. It focused on the development of novel bile acid modulators to treat orphan pediatric liver diseases and other liver and gastrointestinal diseases and disorders. Albireo Pharma Inc., formerly known as BIODEL INC., is based in Boston, United States....

See More

Key Turning Points

2nd Resistance Point 26.40
1st Resistance Point 25.84
Last Price 25.29
1st Support Level 24.86
2nd Support Level 24.44

See More

52-Week High 39.35
Fibonacci 61.8% 31.61
Fibonacci 50% 29.22
Fibonacci 38.2% 26.84
Last Price 25.29
52-Week Low 19.10

See More

Add Data Columns to this Table
Learn about our Custom Views
Want to use this as
your default charts setting?
Learn about our Custom Templates
Switch the Market flag
above for targeted data.
Open the menu and switch the
Market flag for targeted data.
Get Streaming Chart Updates
Switch your Site Preferences
to Interactive Chart
Read About Upcoming
Changes to This Feature
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar